Bank of New York Mellon
HCAT icon

Bank of New York Mellon’s Health Catalyst HCAT Stock Holding History

Bank of New York Mellon’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$159K Sell
79,828
-186,825
-70% -$270K ﹤0.01% 4171
2026
Q1 		$339K Buy
266,653
+444
+0.2% +$835 ﹤0.01% 3800
2025
Q4 		$636K Buy
266,209
+36,950
+16% +$101K ﹤0.01% 3476
2025
Q3 		$653K Buy
229,259
+14,653
+7% +$50.2K ﹤0.01% 3446
2025
Q2 		$809K Buy
214,606
+15,806
+8% +$62.2K ﹤0.01% 3236
2025
Q1 		$901K Sell
198,800
-1,238,206
-86% -$6.55M ﹤0.01% 3131
2024
Q4 		$10.2M Sell
1,437,006
-865,743
-38% -$6.89M ﹤0.01% 1917
2024
Q3 		$18.7M Buy
2,302,749
+72,947
+3% +$527K ﹤0.01% 1611
2024
Q2 		$14.2M Sell
2,229,802
-259,263
-10% -$1.66M ﹤0.01% 1765
2024
Q1 		$18.7M Buy
2,489,065
+1,270,777
+104% +$11.6M ﹤0.01% 1613
2023
Q4 		$11.3M Buy
1,218,288
+363,392
+43% +$2.97M ﹤0.01% 1919
2023
Q3 		$8.65M Buy
854,896
+473,323
+124% +$5.65M ﹤0.01% 2029
2023
Q2 		$4.77M Buy
381,573
+193,591
+103% +$2.31M ﹤0.01% 2352
2023
Q1 		$2.19M Sell
187,982
-1,669
-0.9% -$21.3K ﹤0.01% 2756
2022
Q4 		$2.02M Sell
189,651
-690,414
-78% -$6.67M ﹤0.01% 2851
2022
Q3 		$8.54M Buy
880,065
+80,638
+10% +$1.07M ﹤0.01% 1987
2022
Q2 		$11.6M Buy
799,427
+49,031
+7% +$836K ﹤0.01% 1849
2022
Q1 		$19.6M Buy
750,396
+35,022
+5% +$994K ﹤0.01% 1686
2021
Q4 		$28.3M Sell
715,374
-15,223
-2% -$694K 0.01% 1516
2021
Q3 		$36.5M Buy
730,597
+44,865
+7% +$2.45M 0.01% 1347
2021
Q2 		$38.1M Buy
685,732
+39,892
+6% +$2.13M 0.01% 1346
2021
Q1 		$30.2M Sell
645,840
-69,679
-10% -$3.38M 0.01% 1463
2020
Q4 		$31.1M Sell
715,519
-19,067
-3% -$703K 0.01% 1355
2020
Q3 		$26.9M Sell
734,586
-18,761
-2% -$637K 0.01% 1279
2020
Q2 		$22M Buy
753,347
+598,897
+388% +$16.5M 0.01% 1390
2020
Q1 		$4.04M Buy
154,450
+118,738
+332% +$3.63M ﹤0.01% 2182
2019
Q4 		$1.24M Buy
35,712
+16,725
+88% +$554K ﹤0.01% 3130
2019
Q3 		$601K Buy
+18,987
New +$747K ﹤0.01% 3434

Other funds holding HCAT

Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1.16B AUM 53.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
7WCP
71 West Capital Partners Boston, Massachusetts $2.89B AUM
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
PWM
Perigon Wealth Management San Francisco, California $6.36B AUM 28.76% 1-Year Est. Return

Bank of New York Mellon's HCAT Position: Q2 2026 in Review

Bank of New York Mellon reduced its Health Catalyst (HCAT) stake by 70% in Q2 2026, selling an estimated $270K and leaving 79,828 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #4171.

Bank of New York Mellon first reported a position in HCAT in Q3 2019 and has held it in 28 quarters since. The position peaked at $38.1M in Q2 2021. 51 funds tracked by Wall St. Rank hold HCAT as of Q2 2026.

  • Bank of New York Mellon held 79,828 shares of Health Catalyst worth $159K as of Q2 2026.
  • Bank of New York Mellon sold 186,825 Health Catalyst shares in Q2 2026, an estimated $270K.
  • Health Catalyst made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4171 holding.
  • Bank of New York Mellon first reported a position in Health Catalyst in Q3 2019 and has held it in 28 quarters since.
  • Bank of New York Mellon's Health Catalyst position peaked at $38.1M in Q2 2021.
  • 51 funds tracked by Wall St. Rank held Health Catalyst as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.